Aravive, Inc. (NASDAQ:ARAV) Expected to Post FY2027 Earnings of $0.78 Per Share

Aravive, Inc. (NASDAQ:ARAV – Get Rating) – Equities researchers at HC Wainwright upped their FY2027 earnings estimates for shares of Aravive in a research note issued to investors on Wednesday, March 15th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.78 per share for the year, up from their previous estimate of $0.64. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Aravive’s current full-year earnings is ($1.38) per share.

Separately, EF Hutton Acquisition Co. I reaffirmed a “buy” rating and set a $10.00 price target on shares of Aravive in a research note on Tuesday, February 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Aravive currently has an average rating of “Buy” and an average price target of $9.20.

Aravive Stock Performance

Shares of NASDAQ ARAV opened at $1.96 on Friday. The firm has a market capitalization of $117.27 million, a P/E ratio of -0.83 and a beta of 2.35. Aravive has a one year low of $0.58 and a one year high of $2.23. The company’s fifty day moving average is $1.84 and its two-hundred day moving average is $1.41.

Hedge Funds Weigh In On Aravive

Institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in shares of Aravive by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock valued at $370,000 after acquiring an additional 97,116 shares in the last quarter. Geode Capital Management LLC increased its position in Aravive by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 142,787 shares of the company’s stock worth $188,000 after buying an additional 6,238 shares during the period. Two Sigma Investments LP acquired a new stake in Aravive in the fourth quarter worth $167,000. Millennium Management LLC grew its stake in shares of Aravive by 58.9% in the second quarter. Millennium Management LLC now owns 96,838 shares of the company’s stock worth $96,000 after purchasing an additional 35,900 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Aravive by 271.9% in the fourth quarter. Jane Street Group LLC now owns 42,115 shares of the company’s stock worth $56,000 after purchasing an additional 30,792 shares in the last quarter. 16.85% of the stock is owned by institutional investors and hedge funds.

About Aravive

(Get Rating)

Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.